FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1934-1936 November 4, 2004 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Ruggenenti, P. Related Article by Barnett, A. H. PubMed Citation

Economic issues sometimes seem to be the primary considerations in discussions of treatment for nephropathy in patients with type 2 diabetes. But in the end, the economics of treatment are driven by clinical issues, many of which have yet to be resolved. For example, in the United States, type 2 diabetes is the leading cause of end-stage renal disease; it accounted for approximately 40 percent of cases in patients who began dialysis between 1994 and 1999. Worse yet, the worldwide incidence of end-stage renal disease among patients with type 2 diabetes is expected to double by 2010. These depressing data . . . [Full Text of this Article]

Source Information

From the Renal Division, University of Texas Medical Branch, Galveston.

This article has been cited by other articles:

• Sasso, F. C., De Nicola, L., Carbonara, O., Nasti, R., Minutolo, R., Salvatore, T., Conte, G., Torella, R., for the NID-2 (Nephropathy in Diabetes-Type 2) Stu, (2006). Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy.. Diabetes Care 29: 498-503 [Abstract] [Full Text]  
• Kimmel, P. L. (2006). Update in nephrology and hypertension.. ANN INTERN MED 144: 281-285 [Full Text]